Literature DB >> 24464529

Cilostazol improves hippocampus-dependent long-term memory in mice.

Shuichi Yanai1, Yuki Semba, Hideki Ito, Shogo Endo.   

Abstract

RATIONALE: Phosphodiesterases (PDEs) play an important role in the regulation of intracellular signaling mediated by cyclic adenosine monophosphate (cAMP). Recently, several PDE inhibitors were assessed for their possible cognitive enhancing properties. However, little is known about the effect of PDE3 inhibitors on memory function.
OBJECTIVES: We examined how the PDE3 inhibitor cilostazol affects C57BL/6 J mice as they perform various behavioral tasks. After behavioral assessment, brains of the mice were analyzed immunohistochemically to quantify the phosphorylation of cAMP-responsive element binding protein (CREB), a downstream component of the cAMP pathway.
RESULTS: Oral administration of cilostazol significantly enhanced recollection of the exact platform location in the Morris water maze probe test. Cilostazol also improved context-dependent long-term fear memory, without affecting short-term memory. No apparent effect was observed in cue-dependent fear memory. The results suggest that cilostazol selectively improves hippocampus-dependent long-term memory in these tasks. Cilostazol also significantly increased the number of phosphorylated-CREB-positive cells in hippocampal dentate gyrus.
CONCLUSIONS: These results suggest that cilostazol may exert its beneficial effects on learning and memory by enhancing the cAMP system in hippocampus, where it increases intracellular cAMP activity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24464529     DOI: 10.1007/s00213-014-3442-4

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  77 in total

1.  Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning.

Authors:  R G Phillips; J E LeDoux
Journal:  Behav Neurosci       Date:  1992-04       Impact factor: 1.912

2.  The PDE4 inhibitor rolipram reverses object memory impairment induced by acute tryptophan depletion in the rat.

Authors:  K Rutten; C Lieben; L Smits; A Blokland
Journal:  Psychopharmacology (Berl)       Date:  2007-01-30       Impact factor: 4.530

3.  Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues.

Authors:  Viktor Lakics; Eric H Karran; Frank G Boess
Journal:  Neuropharmacology       Date:  2010-05-21       Impact factor: 5.250

4.  Stereochemistry of hydrolysis by snake venom phosphodiesterase.

Authors:  P M Burgers; F Eckstein; D H Hunneman
Journal:  J Biol Chem       Date:  1979-08-25       Impact factor: 5.157

5.  Effects of a phosphodiesterase IV inhibitor rolipram on microsphere embolism-induced defects in memory function and cerebral cyclic AMP signal transduction system in rats.

Authors:  Akira Nagakura; Makiko Niimura; Satoshi Takeo
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

Review 6.  Anti-dementia drugs and hippocampal-dependent memory in rodents.

Authors:  Carla M Yuede; Hongxin Dong; John G Csernansky
Journal:  Behav Pharmacol       Date:  2007-09       Impact factor: 2.293

7.  Temporally graded retrograde amnesia of contextual fear after hippocampal damage in rats: within-subjects examination.

Authors:  S G Anagnostaras; S Maren; M S Fanselow
Journal:  J Neurosci       Date:  1999-02-01       Impact factor: 6.167

8.  The absorption, distribution and excretion of a new antithrombotic and vasodilating agent, cilostazol, in rat, rabbit, dog and man.

Authors:  H Akiyama; S Kudo; T Shimizu
Journal:  Arzneimittelforschung       Date:  1985

9.  Evaluation of antidepressant and anxiolytic activity of phosphodiesterase 3 inhibitor - cilostazol.

Authors:  Dipesh S Patel; Indermeet Singh Anand; Parloop A Bhatt
Journal:  Indian J Psychol Med       Date:  2012-04

Review 10.  Inducible cAMP early repressor (ICER) and brain functions.

Authors:  Gilyana Borlikova; Shogo Endo
Journal:  Mol Neurobiol       Date:  2009-05-13       Impact factor: 5.590

View more
  5 in total

Review 1.  PDE3 Inhibitors Repurposed as Treatments for Age-Related Cognitive Impairment.

Authors:  Shuichi Yanai; Shogo Endo
Journal:  Mol Neurobiol       Date:  2018-10-11       Impact factor: 5.590

Review 2.  New therapeutic approaches for Alzheimer's disease and cerebral amyloid angiopathy.

Authors:  Satoshi Saito; Masafumi Ihara
Journal:  Front Aging Neurosci       Date:  2014-10-20       Impact factor: 5.750

Review 3.  Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair.

Authors:  Eric P Knott; Mazen Assi; Sudheendra N R Rao; Mousumi Ghosh; Damien D Pearse
Journal:  Int J Mol Sci       Date:  2017-03-24       Impact factor: 5.923

Review 4.  Therapeutic Potential of Phosphodiesterase Inhibitors against Neurodegeneration: The Perspective of the Medicinal Chemist.

Authors:  Giovanni Ribaudo; Alberto Ongaro; Giuseppe Zagotto; Maurizio Memo; Alessandra Gianoncelli
Journal:  ACS Chem Neurosci       Date:  2020-05-28       Impact factor: 4.418

5.  Data on the optimization of behavioral tasks for senescence-accelerated mouse prone 8 (SAMP8).

Authors:  Shuichi Yanai; Shogo Endo
Journal:  Data Brief       Date:  2016-05-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.